24-27 June 2017 | EACR-AACR Special Conference

4-6 Nov 2017 | BioEurope

Sixth Element Capital is currently managing its first fund: the £70m CRT Pioneer Fund (CPF) to create the future of cancer therapy and diagnosis. CPF invests in oncology focused assets and companies and has a proprietary relationship with Cancer Research Technology (CRT). CPF's investors are the European Investment Fund and Syncona.